BIOS 9132 - Advanced Clinical Trial Methodology by Peace, Karl E.
Georgia Southern University 
Digital Commons@Georgia Southern 
Public Health Syllabi Public Health, Jiann-Ping Hsu College of 
Fall 2016 
BIOS 9132 - Advanced Clinical Trial Methodology 
Karl E. Peace 
Georgia Southern University, Jiann-Ping Hsu College of Public Health, kepeace@georgiasouthern.edu 
Follow this and additional works at: https://digitalcommons.georgiasouthern.edu/coph-syllabi 
 Part of the Public Health Commons 
Recommended Citation 
Peace, Karl E., "BIOS 9132 - Advanced Clinical Trial Methodology" (2016). Public Health Syllabi. 73. 
https://digitalcommons.georgiasouthern.edu/coph-syllabi/73 
This other is brought to you for free and open access by the Public Health, Jiann-Ping Hsu College of at Digital 
Commons@Georgia Southern. It has been accepted for inclusion in Public Health Syllabi by an authorized 
administrator of Digital Commons@Georgia Southern. For more information, please contact 
digitalcommons@georgiasouthern.edu. 
 1 
 Syllabus: BIOS 9132 – Advanced Clinical Trial Methodology 
Jiann-Ping Hsu College of Public Health 
Georgia Southern University 
Hendricks Hall, PO Box 8015 
Statesboro, GA 30460 
Fall 2016 
 
 
 
 
 
 
 
 
 
 
 
Prerequisites:                  Clinical Trial Methodology, Statistical Issues in Drug Research and 
Development, or by permission of instructor. 
 
Catalog Description: Students are introduced to regulatory, scientific, statistical and 
practical aspects of methods inherent in design, monitoring and 
analyzing clinical trials.  Clinical trials in many areas of drug 
development are presented, discussed and critiqued. 
   
Required Textbook: No textbook required.  The course is presented using power points 
developed by the professor. Students are provided copies of the power 
points on a flash drive. However, the CTM Book by Peace and Chen is 
a valuable reference and students are encouraged to obtain. 
 
Secondary Texts:  
 
Peace, K. E., Chen, D (2010): Clinical Trial Methodology; Chapman & Hall/CRC, Taylor 
and Francis Group. 
 
Chen D, Peace KE (2010): Clinical Trial Data Analysis using R; Chapman & Hall/CRC, 
Taylor and Francis Group; ISBN:  978-1-4398-4020-7 
 
Chen, D, Peace KE: Applied Meta-Analysis using R. Chapman & Hall/CRC, Taylor and 
Francis Group; 13: 978-1-4665-0599-5; May, 2013. 
 
Chen D, Sun J, Peace KE [Editors and Author contributors]   (2012): Interval-Censored 
Time-to-Event Data: Methods and Applications"; Chapman & Hall/CRC, Taylor and 
Francis Group; Published July, 2012. 
 
Instructor:  Karl E. Peace 
Office:             1005 Hendricks Hall 
Phone:  912-478-7905 
E-Mail Address: kepeace@georgiasouthern.edu   
                                    peacekarl@frontier.com  
Office Hours:             Wednesday– 3:00 PM – 5:00 PM 
Other times by appointment:  
Students are encouraged to make frequent use of email contact where each    
question will be responded via return email 
Class Meets:  Wednesday – 5:00 AM-to-7:45 PM Fall Semester, 2016 
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Peace, K. E. [Editor and Author contributor] (2008): Design and Analysis of Clinical 
Trials with Time to Event Endpoints; Chapman & Hall/CRC Taylor and Francis 
Group; Boca, ISBN 978-1-4200-6639-5. 
 
Peace, K. E. [Editor and Author contributor] (1992): Biopharmaceutical Sequential 
Statistical Applications. Marcel Dekker, Inc., New York, ISBN 0-8247-8628-9. 
 
Peace, K. E. [Editor and Author contributor] (1990): Statistical Issues in Pharmaceutical 
Drug Development.  Marcel Dekker, Inc., New York, ISBN 0-8247-8290-9. 
 
Peace, K.E. [Editor and author] (1988): Biopharmaceutical Statistics in Drug 
Development. Marcel Dekker, Inc., New York, ISBN 0-8247-7798-0. 
 Course Objectives:   At the end of this course, students will be able to: 
1. Explain the requirements for good protocol development for  biomedical research 
clinical trials and develop the statistical analysis section of such protocols 
2. Describe methodological alternatives to commonly used statistical methods used in  
biomedical research clinical trials when analysis assumptions are not met, and 
describe prerequisites for validity of inference from clinical trials 
3. Interpret results of statistical analyses of data collected from biomedical clinical trials  
4. Develop written and oral presentations based on statistical analyses of  biomedical 
research clinical trials, for both biomedical research professionals and educated lay 
audiences  
5. Identify key federal regulations ‘governing’ the conduct of clinical trials 
6. Discuss the Ethics of Clinical Trial Research 
7. Describe the components of Population Nonlinear, Mixed Effects Modeling 
8. Design, analyze and interpret results of bioequivalence, cancer and non-inferiority 
clinical trials 
9. Describe the issues in group sequential clinical trials and in subset analyses 
10. Describe ‘intention to treat’ and its impact on inference when data are missing and 
methods of imputing missing data 
 
Instructional Methods: Class meetings will be a combination of lecture and class discussion. 
Approximately half of the class meetings will be facilitated via Adobe Connect in real time 
(blended format) and the remainder physically in the classroom. Homework assignments – 
including a research project that requires class participation and the final examination constitute 
the basis of student evaluation.   Students are expected to make use of ample office hours to 
discuss concepts or difficulties they may have. 
 
Daily Study Log:  Students are required to keep a daily computerized study log.  The study log 
should have a column for the date, a column to identify topic of study, a column to identify the 
time of beginning study, a column to identify the ending time of study, and a column to identify 
the amount of time spent in studying the topic. 
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Grading:  Weighting of assignments for purposes of grading will be as follows: 
 
Final Exam (objectives 1-14, integrated)………………………………………...60% 
Homework & Research Project Assignments (objectives 1-14, individually)…..30% 
Class Participation (objectives 1-14, individually)………………………………10% 
____ 
Total Possible                                                           100% 
    
The following point scale will be utilized in grading: 
 
90% - 100% A 
80% -   90% B 
70% -   80% C 
60% -   70% D 
  
There are times when extraordinary circumstances occur (e.g., serious illness, death in the 
family, etc.).  In such circumstances, and/or if you need additional time to satisfactorily complete 
any course requirement, please consult with the instructor within a reasonable amount of time.   
 
Academic Misconduct: As a student registered at this University, it is expected that you will 
adhere to only the strictest standards of conduct.   Your continued enrollment in this course is an 
implied contract between you and the instructor on this issue; from this point forward, it is 
assumed that you will conduct yourself appropriately. 
 
Academic integrity relates to the appropriate use of intellectual property.  The syllabus, lecture 
notes, and all materials presented and/or distributed during this course are protected by copyright 
law.  Students are authorized to take notes in class, but that authorization extends only to making 
one set of notes for personal (and no other) use.  As such, students are not authorized to sell, 
license, commercially publish, distribute, transmit, display, or record notes in or from class 
without the express written permission of the instructor. 
 
Plagiarism:  Plagiarism includes (but is not limited to): A. Directly quoting the words of others 
without using quotation marks or indented format to identify them. B. Using published or 
unpublished sources of information without identifying them. C. Paraphrasing material or ideas 
without identifying the source. D. Unacknowledged use of materials prepared by another person 
or agency engaged in the selling of term papers or other academic material. 
 
Attendance Policy: Federal regulations require attendance be verified prior to distribution of 
financial aid allotments.  Students are expected to attend all classes, whether taking for credit or 
auditing (Instructor will permit missing 1-2 classes for valid reasons). 
 
One Final Note: The contents of this syllabus are as complete and accurate as possible.  The 
instructor reserves the right to make any changes necessary to the syllabus and course material.  
The instructor will make every effort to inform students of changes as they occur.  It is the 
responsibility of the student to know what changes have been made in order to successfully 
complete the requirements of the course. 
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Advanced Clinical Trial Methodology Content to be Covered During the Semester: 
 
Module I: An Overview of the Regulation of Pharmaceuticals 
Module II: An Overview of the Processes of Discovery, Basic Research, Clinical Development 
and Manufacturing in Pharmaceutical Development 
Module IIII: Ethics of Clinical Trial Research 
Module IV: Overview of Biostatistical Aspects of Clinical Drug Development 
A. The Components of a Protocol  
B. Statistical Analysis Section of a Clinical Trial Protocol 
C. The Statistical Analysis Plan 
Module V: Statistical Analysis Plan 
Module VI: Validity of Statistical Inference 
Module VII: Population Nonlinear, Mixed Effects Modeling of Primary Efficacy Endpoint in    
                     Enrichment Trials of Alzheimer’s disease 
Module VIII: Biostatistical Aspects of the Design of Cancer Trials 
Module IX: Biostatistical Aspects of the Analysis and Interpretation of Cancer Clinical Trials 
Module X: Interim Analyses: p-Value and Power Computations in Group Sequential Trials 
Module XI: Statistical Analysis of Dose Response Trials 
Module XII: Safety Assessment in Clinical Trials 
Module XIII: Subgroup Analyses in Clinical Trials from a Causal Inference Viewpoint 
Module XIV: Statistical Paradigms and Methodologies for Clinical Development 
Module XV: Biosimilarity  
Module XVI: A Clinical Trial to Reduce CHD Risk 
Module XVII: Intention-to-Treat and Inferential Impact of Missing Data  
Module XVIII: Methods for Imputing Missing Data  
Module XIX: Overview of Meta-Analyses  
Module XX: Design and Analysis of Non-inferiority Clinical trials  
Module XXI: Sample size Considerations if Premarket approval trials 
Module XXII: Number needed to treat (NNT) 
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Student Information  (ADV CTM Class): 
 
      Print Full Name                     email address                Pledge to spend enough time                 
                                                                                         to master material? Circle one. 
 
1. ________________          ________________            Yes          No       Undecided 
 
2. ________________          ________________            Yes          No       Undecided 
  
3. ________________          ________________            Yes          No       Undecided 
 
4. ________________          ________________            Yes          No       Undecided 
 
5. ________________          ________________            Yes          No       Undecided 
 
6. ________________          ________________            Yes          No       Undecided 
 
7. ________________          ________________            Yes          No       Undecided 
 
8. ________________          ________________            Yes          No       Undecided 
 
9. ________________          ________________            Yes          No       Undecided 
 
10. ________________          ________________          Yes          No       Undecided 
